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Summary
Proteins are co-translationally inserted into the endoplasmic
reticulum (ER) where they undergo maturation. Homeostasis in
the ER requires a highly sensitive and selective means of quality
control. This occurs through ER-associated degradation (ERAD).
This complex ubiquitin-proteasome–mediated process involves
ubiquitin conjugating enzymes (E2) and ubiquitin ligases (E3),
lumenal and cytosolic chaperones, and other proteins, including
the AAA ATPase p97 (VCP; Cdc48 in yeast). Probing of processes
involving proteasomal degradation has generally depended on
proteasome inhibitors or knockdown of specific E2s or E3s. In this
issue of PLoS Biology, Ernst et al. demonstrate the utility of
expressing the catalytic domain of a viral deubiquitylating enzyme
to probe the ubiquitin system. Convincing evidence is provided
that deubiquitylation is integral to dislocation of ERAD substrates
from the ER membrane. The implications of this work for
understanding ERAD and the potential of expressing deubiqui-
tylating enzyme domains for studying ubiquitin-mediated process-
es are discussed.
The Endoplasmic Reticulum, Protein Synthesis,
and Degradation
The membranous network that constitutes the endoplasmic
reticulum (ER) plays essential roles in all metabolically active
eukaryotic cells. The ER is contiguous with the nuclear envelope,
yet it extends throughout the cytoplasm contacting mitochondria
and coming in close proximity to the plasma membrane. This
organelle plays important roles in cell metabolism, regulation of
apoptosis, signal integration via calcium signaling, and sensing of
the cell’s microenvironment. Importantly, the ER is the port of
entry for the vast majority of newly synthesized proteins that
traverse the interconnected secretory and endocytic pathways.
Proteins that are not normally occupants of the ER are
transported by vesicular trafficking to the Golgi network. From
there, these proteins reach their ultimate destinations as resident
proteins of the secretory or endocytic pathways or the plasma
membrane; alternatively, they are secreted from the cell. Proteins
that enter the ER and traverse these pathways can constitute up to
a third of synthesized proteins. It is therefore essential that the
functional status of the ER be continually monitored.
In general, proteins are co-translationally inserted into the ER
through a narrow aqueous channel known as the Sec61 translocon
[1]. This is coupled to early steps in protein maturation that can
include the addition of N-linked oligosaccharides, which undergo
further modification in the Golgi network, and complex
chaperone-mediated folding that is often integrally associated
with the formation of highly specific disulfide bonds [2,3]. In many
cases, these newly synthesized proteins also begin the process of
assembly into complexes that ultimately result in functional
receptors or channels. This requires that components ‘‘find each
other’’ in the ER and oligomerize in a highly specific and ordered
manner through interactions involving domains in the lumen of
the ER and the ER membrane as well as their cytoplasmic
domains.
The complexity of the processes involved in protein folding and
assembly and the need to regulate levels of critical resident
proteins of the ER, such as HMG CoA reductase, requires the ER
to have efficient and regulated means to dispose of unwanted
proteins. Thus, much effort was expended in the 1980s and early
990s towards identifying a proteolytic system in the ER or another
pre-Golgi compartment using models including the pre-Golgi
degradation of unassembled components of the T cell antigen
receptor (TCR) [4]. Eventually it became apparent that degrada-
tion of these unassembled subunits as well as other proteins does
not occur within the secretory pathway. Instead, ER proteins are
targeted for export to the cytosol where they are degraded, much
as their cytosolic counterparts, by the ubiquitin-proteasome system
(UPS) [5–9]. This takes place through a coordinated process
known as ER-associated degradation (ERAD) [3,10,11] (vide infra).
ER Stress and the Unfolded Protein Response
Imbalance between neo-synthesis, degradation, and transport
through the secretory pathway results in ‘‘ER stress’’ that, if left
uncompensated, threatens cell function and survival and is linked
to numerous pathologies, including neurodegenerative diseases,
cancer, and diabetes [12]. In higher eukaryotes, the state of the ER
is continually monitored by at least three ER transmembrane
sensors that each initiate a set of distinct but intersecting signaling
pathways oriented towards maintaining ER homeostasis. This
graded response, which is dependent on the degree of ER stress, is
collectively known as the unfolded protein response (UPR) [13,14].
The UPR upregulates the expression of genes involved in protein
folding, modification, transport, and degradation, as well as redox
regulation. The UPR also results in an increase in expression of
enzymes for lipid biosynthesis, so as to increase the surface area of
the ER. At the same time, the UPR inhibits global protein
translation and reduces protein translation at the ER to reduce the
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to conserve resources and overcome ER stress. If the UPR fails to
restore ER homeostasis, cell death pathways are activated. One
important mechanism for alleviating ER stress is by increasing
degradation from the ER through UPR-mediated upregulation of
ERAD components. Conversely, loss of ERAD components
sensitizes cells to ER stress–induced apoptosis. The quality
control/ERAD system becomes even more important during
cellular stress, when small changes in the cell’s ability to cope with
ER stress can tip the balance towards either death or survival and
proliferation [11].
Endoplasmic Reticulum–Associated Degradation
We now understand that ERAD involves substrate ubiquityla-
tion and proteasomal degradation, which are tightly coupled to
substrate dislocation from the ER. The conjugation of proteins
with ubiquitin is a highly regulated process with specificity
conferred by over 500 different ubiquitin ligases (E3s) working
together with ubiquitin conjugating enzymes (E2s). The specific
consequence of ubiquitylation is largely dependent on the nature
of the polyubiquitin chain formed on target proteins. Besides
proteasomal degradation, modification of proteins with single
ubiquitin or polyubiquitin chains, commonly linked through
different lysines of ubiquitin, can have other proteasome-
independent functions in DNA repair, NF-kB activation, endocy-
tosis, and lysosomal targeting, as well as other processes [16].
Ubiquitylation is opposed by the action of ,100 mammalian
deubiquitylating enzymes (DUBs) [17]. DUBs perform many
functions, including the deubiquitylation of specific substrates and
disassembly of specific ubiquitin linkages (Figure 1).
The ERAD ubiquitylation machinery in both yeast and
mammals consists primarily of ER-resident transmembrane E3s
and their cognate E2s. In several cases, particularly in mammals,
multiple E3s are implicated in the degradation of a specific
substrate. DUBs can counteract the activity of ubiquitin ligases
towards specific ERAD substrates [18], although the roles of
DUBs in ERAD have not been extensively explored.
Intense interest has been focused on identification of the protein
conducting channel(s) through which misfolded proteins can be
exported from the ER to the cytosol—a process variously referred
to as ‘‘retrotranslocation’’ or ‘‘dislocation.’’ Early studies suggested
that Sec61, the import channel for proteins into the ER, might also
be the retrotranslocon through which this dislocation is effected
[8,19–21]. Another such candidate is Derlin-1, a polytopic protein
implicated in the targeting of several substrates for degradation
[22,23]. In addition, polytopic ER-resident ubiquitin ligases such
as Hrd1 have been suggested to form part of this channel [24]. As
Sec61 imports nascent polypeptides into the ER in an unfolded
state, a reasonable assumption is that protein unfolding is likely
required for retrotranslocation. However, it is not evident that this
is uniformly the case [25,26].
For transmembrane proteins with cytosolic domains, the
topological conundrum of being ubiquitylated and degraded from
the ER is easily conceptualized. Exposed domains of substrates
serve as targets for the ubiquitylation machinery associated with
retrotranslocons (Figure 2). Ubiquitylated species are ‘‘ratcheted’’
out of the ER in an ATP-driven process provided by complexes of
the hexameric AAA-ATPase p97 (Cdc48 in yeast) and associated
ubiquitin-binding proteins [27,28]; these complexes are also
implicated as intermediates in the proteasomal targeting of non-
ER proteins [29]. At least in yeast, there is evidence that other
ubiquitin-binding ‘‘shuttle proteins’’ play a role in delivering
dislocated substrates from p97 complexes to proteasomes [30]. For
those proteins that reside in the lumen of the ER, the means by
which they are retrotranslocated is conceptually more difficult to
envision. However, we now understand that lumenal chaperones
can associate with at least one of the transmembrane ubiquitin
ligase complexes and deliver proteins to sites of ubiquitylation
[31,32].
Deubiquitylation as an Integral Step in ERAD
A recent study by Ernst and colleagues has provided a new and
interesting twist to ERAD [33]. The p97 complex has been found
to be associated with several deubiquitylating enzymes, including
YOD1 and USP13 [34]. YOD1 interacts with p97 via its UBX
domain. Transfection of a catalytically inactive form of YOD1
blocks dislocation of model ERAD substrates [33]. This result
suggests that deubiquitylation is required for protein dislocation
from the ER (Figure 2). This is a finding that at first seems
counterintuitive, given the wealth of evidence suggesting a role for
ubiquitylation in this process. One possibility is that, analogous to
threading of the substrate into the narrow channel of the
proteasome, protein dislocation might require trimming off the
polyubiquitin chain to allow the substrate to enter the central
channel of the p97 complex during retrotranslocation. While
highly provocative, these results involve overexpression of a
‘‘dominant negative’’ form of YOD1. This overexpression could
potentially interfere with the binding to p97 of other important
UBX domain-containing components of the ERAD machinery
[35]. Thus, the possibility that the results obtained were an
indirect effect of disrupting other p97 interactions could not be
discounted.
Until now, with few exceptions, probing of the UPS in general
and ERAD in particular has relied on either manipulation of
substrate-specific enzymes of the ubiquitin system or use of
proteasome inhibitors. In the current issue, Ernst and colleagues
[36] unveil a new tool for inhibiting protein degradation—the
catalytic domain of a DUB encoded by the Epstein-Barr virus
(EBV). The authors show that the isolated EBV DUB domain
inhibits degradation of proteasome substrates, likely due to
preemptive removal of ubiquitin from the substrates. Interestingly,
cells tolerate expression of the EBV DUB better than proteasome
inhibitors. They then employ this tool to follow up on the
aforementioned study on the role of DUB activity in protein
dislocation.
By fusing the catalytic domain of EBV DUB with a UBX
domain, Ernst et al. target the EBV DUB domain to p97-
containing complexes. Expression of this UBX-EBV DUB also
results in accumulation of ERAD substrates. For two model
substrates, a mutant ribophorin RI332 and TCRa, accumulation of
deglycosylated intermediates suggest that these proteins are largely
dislocated, since N-glycanase, which is responsible for removing
N-linked oligosaccharides from proteins, is confined to the cytosol.
Subcellular fractionation and microscopy confirm that the
substrates are dislocated but remain loosely associated with the
ER membrane. The authors then take advantage of this p97-
targeted DUB to further probe the role of ubiquitylation during
ERAD. Strikingly, expression of UBX-EBV DUB restores protein
dislocation in the presence of catalytically inactive YOD1. The
dislocated substrates accumulate in the cytosol as deglycosylated
and deubiquitylated intermediates. These results reinforce the idea
that deubiquitylation is necessary for substrate dislocation.
However, as the EBV DUB overcomes the inhibitory effect
of inactive YOD1 even when not targeted to p97 via a UBX
domain, it leaves unanswered whether, for endogenous DUBs, p97
association is truly required for their recruitment to the ER and
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whether the critical targets for this deubiquitylation step are the
ERAD substrates, although this is certainly the most likely
scenario. Such a model would then require at least two rounds
of ubiquitylation to occur during ERAD. The first round is
essential for p97 recognition and dislocation. The second round,
following substrate deubiquitylation, is essential for proteasomal
targeting of the now dislocated protein.
Cytosolic Chaperones in ERAD
As proteins dislocated from the ER may be partially unfolded,
an important question is how they are maintained in a soluble
form in the cytosol. Previous studies have shown that cytosolic
chaperones are involved in the degradation of certain ERAD
substrates [37–40]. Employing chemical inhibitors or mutants of
the dislocation machineries, Ernst et al. utilized mass spectrometry
to identify proteins interacting with a model ERAD substrate,
RI332, when protein dislocation is disrupted at different stages.
This approach should in principle allow for a systematic and
unbiased discovery of factors involved in the various stages of
ERAD. For example, expression of UBX-EBV DUB or treatment
with proteasome inhibitors arrests some percentage of the sub-
strate at a step after dislocation. Under these conditions, RI332
associates with cytosolic chaperones, supporting the idea that a
cytosolic chaperone network buffers the dislocated substrate and
allows their subsequent degradation by the proteasome. The role
of these cytosolic chaperones in ERAD awaits further studies.
Future Directions
These recent findings raise new questions regarding ERAD and
illustrate the utility of DUBs in studying the UPS. If substrate
deubiquitylation is required for retro-translocation, an important
question now becomes what components of UPS participate in the
subsequent proteasomal-targeting step of dislocated substrates. As
dislocated substrates stay loosely associated with the ER
membrane, it would be interesting to determine whether this
second round of ubiquitylation is carried out by the same ERAD
ubiquitin ligases that initiate dislocation, or whether cytosolic
ubiquitin ligases now assume control. If cytosolic ubiquitin ligases
are involved, are they specialized for dislocated substrates or do
they overlap with those implicated in cytosolic quality control? In
this regard, it is of note that HSP70-associated E3s including
Figure 1. Roles of ubiquitylation in cellular regulation. Conjugation of ubiquitin onto protein substrates requires at least three enzymes. One
of two ubiquitin activating enzymes (E1) activates ubiquitin through an ATP-dependent step, forming a thioester linkage between the active site
cysteine of E1 and the C-terminal carboxylate of ubiquitin. E1 then transfers the ubiquitin to the active site cysteine of one of approximately 40
mammalian ubiquitin conjugating enzymes (E2). The ubiquitin can be transferred to the active site of a HECT domain ubiquitin ligase (E3), which
binds the substrate and mediates the conjugation of ubiquitin. RING finger and related E3s function as allosteric activators of E2, promoting the
transfer of ubiquitin directly from the E2 to the substrate. The combination of E2/E3 determines the length and type of polyubiquitin chains
assembled on the substrate, which can lead to diverse cellular effects, some of which are noted. Ubiquitylation is best characterized as modifying
primary amines (lysines and the N-termini of proteins) [44]. More recently, there has been evidence that other nucleophillic amino acids including
serine, threonine, and cysteine can also be modified with polyubiquitin chains [45–48]. DUBs perform a number of cellular roles, including removing
ubiquitin from specific substrates. There are at least five classes of DUBs, and many DUBs show strong preferences for specific polyubiquitin chain
linkages.
doi:10.1371/journal.pbio.1001038.g001
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ERAD substrates [41,42].
A major point accentuated by the current findings of Ernst et al.
[36] is that DUB catalytic domains can be used to inhibit and
probe the ubiquitin conjugating system in ways that might not be
achieved by proteasome inhibitors. While the use of such domains
can provide important new insights, interpretation of results
obtained using these tools have important caveats. These include
the fact that, aside from subcellular localization, outcome of
expressing a DUB domain will likely be highly dependent on its
Figure 2. Models for ERAD. (a–c) Classical view of ERAD. (a) ERAD substrate (black) is recognized by ER chaperones and partially translocated
through a protein conducting channel complex/retrotranslocon (brown). The substrate is conjugated with chains of ubiquitin by an ER-resident
ubiquitin ligase (E3) and its cognate ubiquitin conjugating enzyme (E2) on the cytosolic face of the ER membrane. (b) The p97 complex, comprising a
hexamer of the AAA ATPase p97 and accessory proteins such as Ufd1 and Npl4 (not depicted), associates with the retrotranslocation complex,
recognizes the polyubiquitin chain and extracts the ubiquitylated substrate to the cytosol. (c) Polyubiquitin chains target the dislocated substrate to
the 26S proteasome (magenta) for degradation, in some cases assisted by shuttle proteins (pink) that bind both to ubiquitin chains and the
proteasome. (d–f) Model based on results in Ernst et al. [33,36]. The exact mechanism by which the p97 complex extracts the substrate is not well
understood. These new findings suggest that (d) the p97 complex recognizes polyubiquitin chains on the substrate as it moves through the protein-
conducting channel. (e) DUBs associated with the p97 complex (purple) or potentially free in the cytosol (green) trim off the polyubiquitin chain on
the substrate, allowing it to be threaded into the narrow channel of the p97 complex. (f) The dislocated substrate is ubiquitylated a second time by
either ER-resident or cytosolic E3s for targeting to the proteasome (depicted in [c]).
doi:10.1371/journal.pbio.1001038.g002
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specificity of DUBs for different polyubiquitin chain linkages varies
considerably. Therefore, results obtained with expression of
particular DUBs will need to be interpreted in this context.
Another attractive means of utilizing DUB catalytic domains is
to covalently fuse them with proteins that have restricted
subcellular localization to probe specific functions of ubiquitylation
in the cell. An isolated DUB catalytic domain can also be fused to
the target protein to inhibit ubiquitylation of the fusion protein.
This strategy has recently allowed the dissection of the role of
ubiquitylation in endosomal targeting in yeast [43]. This
approach, as well as variations on the one employed in this issue,
opens up exciting new possibilities for probing the function of
ubiquitylation in cellular regulation.
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